This website uses only technical or equivalent cookies.
For more information click here.

Register Login Submit an Article

JOURNAL OF PSICOPATHOLOGY

Reviews

Vol. 30: Issue 1 - March 2024

Non-pharmacological interventions to improve cognitive impairment and psychosocial functioning in schizophrenia: a critical review

Authors

Gabriele Nibbio , Irene Calzavara Pinton , Lorenzo Bertoni , Antonio Cicale , Nicola Necchini , Daniela Zardini , Laura Poddighe , Jacopo Lisoni , Giacomo Deste , Stefano Barlati , Antonio Vita

Key words: cognition, cognitive remediation, functioning, non-invasive brain stimulation, physical exercise, schizophrenia
DOI: 10.36148/2284-0249-N455
Publication Date: 2024-02-20

Abstract

Cognitive impairment represents one of the core features of Schizophrenia Spectrum Disorders (SSD) and has a significant negative impact on psychosocial functioning and real-world outcomes of people living with SSD. While currently available pharmacological treatments do not appear to provide significant improvements in cognitive performance, some non-pharmacological interventions have shown to reliably provide cognitive gains and consequent improvements of psychosocial functioning in SSD. The present critical review focuses on the evidence of effectiveness and on the limitations of these interventions. Cognitive remediation and physical exercise-based interventions appear to provide improvements in both cognitive performance and psychosocial functioning, with clear moderators of effects and with abundant scientific evidence supporting their clinical usefulness. Non-invasive brain stimulation techniques such as transcranial direct current stimulation and transcranial magnetic stimulation appear as promising interventions, but more research is currently needed to better assess the optimal modalities of delivering these treatments to people with SSD. More research is currently needed to better understand barriers and facilitators of implementation in clinical practice of these interventions, and more organization, policymakers and clinicians efforts are required to deliver them to people living with SSD in a consistent manner.

Introduction

Schizophrenia Spectrum Disorders (SSD) are severe and debilitating mental conditions, and people living with SSD often show limitations in real-world functional outcomes 1,2, reduced quality of life 3,4, high levels of internalized stigma 5-7 and low levels of life engagement 8,9.

Cognitive impairment represents one of the core features of SSD 10-12 that can be observed in the vast majority of diagnosed individuals 13,14 even before the clinical onset of the disorder 15-17, interesting both neurocognitive 10,18,19 and social cognition domains 20-22. In fact, the prevalence and the relevance of cognitive impairment in SSD has recently led the international scientific community to devise and use with an increasing frequency the term Cognitive Impairment Associated with Schizophrenia (CIAS) 23.

The relevance of CIAS in a clinical perspective is also determined by the fact that it represents one of the main determinants of real-world functional impairment in SSD 24-27 and of worse long-term real-world outcomes 28-30.

Currently available pharmacological treatment appears to offer only minimal improvement in CIAS: while an accurate management of antipsychotic medications and of pharmacological therapy in general are essential to avoid further worsening of CIAS 31,32, and some interesting molecules have shown promising preliminary evidence of effectiveness 33-36, no pharmacological agent is currently indicated for the treatment of CIAS 37,38.

However, several non-pharmacological interventions have been developed and are provided to people living with SSD 39, and some of them have shown consistent evidence of effectiveness in treating CIAS and in translating cognitive gains into improvements in real-world psychosocial functioning.

The present paper aims to provide a critical review on the state of the art of non-pharmacological interventions in treating CIAS, focusing on the most recent evidence on the effectiveness and on the limitations of currently available treatments. A summary is reported in Table I.

Cognitive remediation

Cognitive Remediation (CR) is a training-based behavioral intervention specifically designed to treat CIAS with the long-term aim of improving psychosocial functioning and real-world outcomes in a durable manner 40,41.

Several recent systematic review and meta-analyses have shown that CR interventions targeting neurocognitive domains and social cognition domains provide reliable improvements in CIAS that are well translated into functional gains 42-45. The presence of an active and trained therapist delivering the intervention, the development of novel cognitive strategies and the use of techniques to facilitate the transfer of cognitive improvements in the real world, as well as the structured integration with psychiatric rehabilitation programs and the combination with other evidence-based interventions all represent elements that consistently improve the outcomes of CR; no patient characteristic appears to substantially limit the effectiveness of CR in rehabilitation contexts, but participants with a more compromised clinical presentation could obtain greater benefits 44. In fact, an individual-patient meta-analysis including several different study samples showed that age does not represent a significant moderator of effect, suggesting that CR is feasible also in older patients 46.

This wealth of evidence attesting the effectiveness of CR on its main treatment targets and the identification of moderators of effectiveness resulted in the attribution to CR of the highest degree of recommendation in the European Psychiatric Association guidance dedicated to the treatment of CIAS 32.

Even more recently, another meta-analysis has shown that CR has a good acceptability profile, in line with that of other psychosocial interventions routinely used in the rehabilitation practice and delivered to people living with SSD 47. A systematic review focused on factors influencing access and engagement of CR interventions, reporting that more severe CIAS and negative symptoms, lower intrinsic motivation and higher baseline self-efficacy resulted were observed in drop-outs 48. A recent trial confirmed that CR is equally effective in pharmacological treatment responders and people with treatment-resistant SSD, further supporting the notion that subjects with a more severe clinical presentation might consistently benefit from receiving CR 49. Another study focused on moderators of functional improvements after CR reported that participants who were more clinically compromised, older and with lower education level obtained greater improvements 50.

Despite the consistent evidence of effectiveness and the clear recommendation provided in international guidance to deliver CR to people living with SSD, this intervention, as well as other evidence-based non-pharmacological treatments, are still unevenly implemented in the routine clinical practice of mental health services, even in high-income countries 51,52. This is particularly problematic as recent evidence shows that CR interventions can be effectively implemented in day-to-day rehabilitation settings 53,54 even in contexts with limited available resources and low incomes 55.

In this perspective, future studies should focus on identifying and assessing facilitators and barriers to the implementation of CR in clinical practice, with particular attention dedicated to practical and feasible ways to strengthen facilitators and overcome barriers.

One possible instrument to facilitate access to services and to evidence-based treatment is represented by novel digital technologies, such as telemedicine: in fact, recent studies show that remotely delivered CR interventions appear to be feasible as well as engaging and well accepted by participants 56-59. More research is currently needed and warranted in order to further attest the effectiveness of this approach on cognitive and functional outcomes: if this type of approach provided results that are similar to those obtained with in-person CR interventions in a reliable manner, it could represent a valuable asset to improve treatment access.

Another technology that could be of considerable interest in the context of delivering CR interventions is virtual reality: immersive virtual reality programs could provide more engaging exercises, improving participation and acceptability of the intervention, and ecologically valid scenarios could improve and facilitate the transfer of cognitive gains into real-world psychosocial functioning outcomes 60,61. However, more high-quality studies are currently required in order to assess whether virtual reality CR interventions consistently provide superior effects compared to standard CR programs. The comparison between virtual reality and standard CR interventions should also take into account cost-effectiveness analyses, as virtual reality devices and programs are still currently characterized by elevated prices. In fact, cost-effectiveness analyses of CR represents another field that requires further studies: while several reports show that CR does indeed represent a valid intervention also in a cost-effectiveness perspective 62-66, the economic requirements of specific interventions and the available resources can change drastically over time and in different contexts, so more research is currently warranted regarding this aspect.

Physical exercise

Physical exercise-based programs, and aerobic exercise in particular, can be considered to all intent and purposes as evidence-based intervention in people living with SSD, as they can reliably improve important outcomes such as metabolic and health-related parameters 67-69 but also core dimensions of the disorder 70-72. In fact, the positive effects of physical exercise interventions in the treatment of CIAS are well documented in several large and high quality meta-analytic works 70,73,74. The European Psychiatric Association guidance dedicated to the treatment of CIAS recommends the use of physical exercise interventions, but with a lower level of recommendation than that of provided for CR: despite the wealth of available evidence, this was mostly due to the lack of systematic assessments of the moderators of effects that could inform clinicians on which type of intervention should be implemented in routine rehabilitation practice and for the lack of systematic assessments of the effects on functional outcomes 32.

However, a recent meta-analysis explored specifically the potential moderators of effect of physical exercise interventions on CIAS: results showed that the most effective form of activity is aerobic exercise, delivered in a group context with the supervision of trained exercise professionals. Cognitive improvements provided by physical exercise also show a dose-response effect, starting from a duration of ≥ 90 min per week for ≥ 12 weeks: this observation strongly suggests that the observed cognitive improvements are directly related to physical exercise 75.

Moreover, another recent meta-analysis investigated the effects of physical exercise in people with SSD focusing specifically on functional outcomes: moderate-sized effects were observed for global functioning, social functioning and daily life functioning, with larger effects in aerobic exercise interventions of moderate to vigorous intensity 76.

In light of the results of these meta-analyses, physical exercise-based interventions can now be fully considered as evidence-based treatments targeting CIAS.

Recent studies show that physical exercise programs can also be easily combined with CR: these combined interventions appear to provide greater benefits than their individual components, granting faster improvements in cognitive performance 77-79.

As regards implementation in clinical services, physical exercise shares the same issues of CR and other evidence-based psychosocial interventions for people with SSD: they are currently implemented in a piecemeal manner and provided unevenly to service users, even in inpatients contexts 51. On one hand, more research is currently needed to better understand facilitators and barriers that influence the implementation of evidence-based psychosocial interventions in clinical settings; on the other hand, greater efforts should be made at policymakers and service organization levels to reduce the bench to bedside gap.

Non-invasive brain stimulation

Beside psychosocial intervention, another category of non-pharmacological treatments that can be provided to people living with SSD consists in bran stimulation techniques, and in particular non-invasive brain stimulation. Non-invasive brain stimulation techniques that have been explored in the specific context of treating CIAS are mostly transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) 80.

TDCS consists in applying low-amplitude direct currents (usually 1-2 mA) through anode and cathode electrodes applied to the scalp, modulating cortical excitability in a nonfocal manner by polarity-dependent shifts of neuronal membrane potentials 81, while TMS provides focal electromagnetic pulses through a wire coil to focally stimulate target brain areas by inducing secondary electric current flows modulating neuronal firing rates 82.

Recent meta-analyses have shown that both tDCS and TMS could have positive effects in the treatment of CIAS 83,84.

In particular, both TMS 85 and tDCS 86-88 appear to provide small improvements in the domain of working memory, with tDCS having a more literature supporting in a consistent manner the evidence of effectiveness.

However, the stimulation protocols implemented in tDCS trials vary in a significant manner, with important differences as regards electrode placement, length and timing of stimulation sessions, and overall duration of the treatment: this methodological heterogeneity could mask the true potential of the treatment, and it can not be excluded that some treatment protocols could provide consistent benefits in CIAS as well as in other core SSD dimensions 89. More studies are currently required in order to better identify the optimal treatment modalities and durations, allowing to properly assess the effectiveness of non-invasive brain stimulation. This represents an essential requirement in order to provide clear recommendations regarding its use in clinical practice.

Moreover, a recent systematic review and meta-analysis compared the effectiveness of combining non-invasive brain stimulation with CR to CR alone on cognitive and functional outcomes: while this work was conducted with a transdiagnostic approach and trials including samples of people with SSD represented a minority of included studies (5 out of 72 included studies), the combined approach appeared to provide superior benefits in the working memory domain 90. This result suggests that a combined treatment approach may indeed be effective also in SSD: however, the Authors highlighted that the vast majority of included studies showed significant risk of bias. These issues warrant the need of further research on the effectiveness of this combination, particularly in SSD samples.

Discussion

While CIAS represents a core feature of SSD that severely impacts real-world outcomes and shows little improvements with pharmacological therapy, different non-pharmacological approaches are currently available for its treatment.

CR and physical exercise-based interventions showed consistent benefits in improving CIAS and can be easily and effectively implemented in routine clinical practice, particularly in rehabilitation and impatient settings. CR directly targets CIAS and has wide literature supporting its consistent effectiveness 43-45. Physical exercise also appears to reliably improve CIAS 74,75, and can also provide substantial benefits on metabolic and health-related outcomes 67,69.

Both interventions appear to provide larger benefits if delivered with an active and trained therapist: in this regard, the training and integration in rehabilitation services of therapists appears to be essential to properly treat CIAS and, consequently, to provide an optimal rehabilitation process and improve recovery in people living SSD. CR and physical exercise can also be combined into structured rehabilitation programs, if available resources allow it, to provide superior benefits 77-79.

Non-invasive brain stimulation, particularly tDCS, may also provide some measure of improvements, but more research is currently needed to better define the optimal stimulation modalities and treatment duration 32. The combination of CR and non-invasive brain stimulation also appears promising, but more high quality studies in SSD samples are currently needed 90.

Despite the existence and the availability of these treatment options, more effort is currently needed to make sure that they are actually delivered to service users: evidence-based non-pharmacological treatments are still provided to service users living with SSD in an uneven and piecemeal manner also in high-income contexts 51. To close, or at least reduce, this bench-to-bedside gap, several action are currently required: more research is needed on facilitators and barriers to treatments implementation; more effort is required at policymakers and service organization levels; national and international clinical practice guidelines should provide clearer and more univocal recommendations on the importance of these treatments; finally, practitioners in clinical settings should be educated on the existence and effectiveness of these treatments, and consider them as options in the routine treatment and clinical management of patients with SSD.

Moreover, even the most effective evidence-based interventions only provide moderate improvements in CIAS: constant effort in research settings is currently required to develop both pharmacological and non-pharmacological treatments that are able to provide larger benefits.

Despite these issues, the available treatments represent valuable assets to improve CIAS, and should be carefully taken into account in the clinical management and in the process of treatment personalization and optimization to improve real-world recovery outcomes of people living with SSD.

Conflicts of interest statement

The Authors declare no conflict of interest in the design, execution, interpretation, or writing of the manuscript.

Funding

None.

Authors’ contributions

SB, GD, GN, AV: study conceptualization and design; GN, ICP, LB, AC, NN, DZ, LP, JL, SB: literature search; GN: wrote the first draft of the manuscript; GN, SB, AV: supervision of the manuscript; all the Authors reviewed and approved the final version of the manuscript.

Ethical consideration

Not applicable.

Figures and tables

Intervention Definition Main outcomes Evidence of effectiveness
Cognitive Remediation Behavioral training-based intervention targeting cognitive performance Cognitive performance, with the aim of providing a durable improvement to psychosocial functioning Cognitive performance and psychosocial functioning 43-45, acceptability 47
Physical Exercise-Based Interventions Interventions including elements of physical training, mostly aerobic exercise Physical fitness, metabolic and health-related outcomes, but in people with SSD also cognitive performance, symptoms severity and psychosocial functioning Metabolic and health related outcomes 70, cognitive performance 74,75, clinical symptoms and psychosocial functioning 71,73,76
Non-Invasive Brain Stimulation Stimulation of target brain areas through low-amplitude direct currents (tDCS) or focal electromagnetic pulses (TMS) Neuronal firing rates and trophism in selected brain areas, resulting in improvement in core SSD dimension such as positive, negative and cognitive symptoms Cognitive performance, mostly in the working memory domain 83-85, particularly for tDCS 86-88
SSD: Schizophrenia Spectrum Disorders; tDCS: transcranial direct current stimulation; TMS: transcranial magnetic stimulation.
TABLE I. Non-pharmacological interventions to improve cognitive impairment in schizophrenia.

References

  1. Galderisi S, Rucci P, Mucci A. The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. World Psychiatry. 2020;19:81-91. doi:https://doi.org/10.1002/wps.20700
  2. Harvey P, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry. 2012;11:73-9. doi:https://doi.org/10.1016/j.wpsyc.2012.05.004
  3. Dong M, Lu L, Zhang L, Zhang Y. Quality of Life in Schizophrenia: A Meta-Analysis of Comparative Studies. Psychiatr Q. 2019;90:519-32. doi:https://doi.org/10.1007/s11126-019-09633-4
  4. Karow A, Wittmann L, Schöttle D. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci. 2014;16:185-95. doi:https://doi.org/10.31887/DCNS.2014.16.2/akarow
  5. Barlati S, Morena D, Nibbio G. Internalized stigma among people with schizophrenia: Relationship with socio-demographic, clinical and medication-related features. Schizophrenia Res. 2022;243:364-71. doi:https://doi.org/10.1016/j.schres.2021.06.007
  6. West M, Yanos P, Smith S. Prevalence of Internalized Stigma among Persons with Severe Mental Illness. Stigma Res Action. 2011;1:3-10. doi:https://doi.org/10.5463/sra.v1i1.9
  7. Yanos P, DeLuca J, Roe D. The impact of illness identity on recovery from severe mental illness: A review of the evidence. Psychiatry Res. 2020;288. doi:https://doi.org/10.1016/j.psychRes2020.112950
  8. Correll C, Ismail Z, McIntyre R. Patient Functioning, Life Engagement, and Treatment Goals in Schizophrenia. J Clin Psychiatry. 2022;83. doi:https://doi.org/10.4088/JCP.LU21112AH2
  9. Vita A, Barlati S, Deste G. Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community. Psychol Med. 2023;53:7943-7952. doi:https://doi.org/10.1017/S0033291723002106
  10. Green M, Horan W, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry. 2019;18:146-61. doi:https://doi.org/10.1002/wps.20624
  11. Maj M, van Os J, De Hert M. The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry. 2021;20:4-33. doi:https://doi.org/10.1002/wps.20809
  12. McCutcheon R, Keefe R, McGuire P. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. Published online 2023:1-17. doi:https://doi.org/10.1038/s41380-023-01949-9
  13. Harvey P, Bosia M, Cavallaro R, Howes O, Kahn R, Leucht S. Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. Schizophr Res Cogn. 2022;29. doi:https://doi.org/10.1016/j.scog.2022.100249
  14. McCleery A, Nuechterlein K. Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues Clin Neurosci. 2019;21:239-48. doi:https://doi.org/10.31887/DCNS.2019.21.3/amccleery
  15. Fusar-Poli P, Deste G, Smieskova R. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry. 2012;69:562-71. doi:https://doi.org/10.1001/archgenpsychiatry.2011.1592
  16. McCleery A, Ventura J, Kern R. Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment. Schizophr Res. 2014;157:33-9. doi:https://doi.org/10.1016/j.schres.2014.04.039
  17. Mollon J, Reichenberg A. Cognitive development prior to onset of psychosis. Psychol Med. 2018;48:392-403. doi:https://doi.org/10.1017/S0033291717001970
  18. Nuechterlein K, Green M, Kern R. The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. Am J Psychiatry. 2008;165:203-13. doi:https://doi.org/10.1176/appi.ajp.2007.07010042
  19. Reichenberg A. The assessment of neuropsychological functioning in schizophrenia. Dialogues Clin Neurosci. 2010;12:383-92. doi:https://doi.org/10.31887/DCNS.2010.12.3/areichenberg
  20. Kalin M, Kaplan S, Gould F. Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia. J Psychiatr Res. 2015;68:254-60. doi:https://doi.org/10.1016/j.jpsychires.2015.07.008
  21. Pinkham A, Penn D, Green M, Harvey P. Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study. Schizophrenia Bulletin. 2016;42:494-504. doi:https://doi.org/10.1093/schbul/sbv056
  22. Savla G, Vella L, Armstrong C, Penn D, Twamley E. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull. 2013;39:979-92. doi:https://doi.org/10.1093/schbul/sbs080
  23. Horan W, Catalano L, Green M. Cognitive Functioning in Schizophrenia: Leveraging the RDoC Framework. (Barch D, Young J, eds.). Springer International Publishing; 2023. doi:https://doi.org/10.1007/7854_2022_382
  24. Deste G, Vita A, Nibbio G, Penn D, Pinkham A, Harvey P. Autistic Symptoms and Social Cognition Predict Real-World Outcomes in Patients With Schizophrenia. Front Psychiatry. 2020;11. doi:https://doi.org/10.3389/fpsyt.2020.00524
  25. Galderisi S, Rucci P, Kirkpatrick B, Mucci A, Gibertoni D, Rocca P. Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia: A Network Analysis. JAMA Psychiatry. 2018;75:396-404. doi:https://doi.org/10.1001/jamapsychiatry.2017.4607
  26. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophrenia Research. 2016;175:154-60. doi:https://doi.org/10.1016/j.schres.2016.04.043
  27. Galderisi S, Rossi A, Rocca P. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13:275-87. doi:https://doi.org/10.1002/wps.20167
  28. Giuliani L, Giordano G, Bucci P. Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses. Front Psychiatry. 2021;12. doi:https://doi.org/10.3389/fpsyt.2021.791117
  29. Mucci A, Galderisi S, Gibertoni D, Rossi A, Rocca P, Bertolino A. Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry. 2021;78:550-9. doi:https://doi.org/10.1001/jamapsychiatry.2020.4614
  30. Vita A, Gaebel W, Mucci A. European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022;65. doi:https://doi.org/10.1192/j.eurpsy.2022.2316
  31. Joshi Y, Thomas M, Braff D. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia. Am J Psychiatry. 2021;178:838-47. doi:https://doi.org/10.1176/appi.ajp.2020.20081212
  32. Vita A, Gaebel W, Mucci A. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022;65. doi:https://doi.org/10.1192/j.eurpsy.2022.2315
  33. Achtyes E, Hopkins S, Dedic N. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273:1543-56. doi:https://doi.org/10.1007/s00406-023-01580-3
  34. O’Donnell P, Dong C, Murthy V. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. Neuropsychopharmacology. 2023;48:1052-9. doi:https://doi.org/10.1038/s41386-023-01560-0
  35. Rosenbrock H, Desch M, Wunderlich G. Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2023;273:1557-1566. doi:https://doi.org/10.1007/s00406-023-01576-z
  36. Sauder C, Allen L, Baker E. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry. 2022;12:1-8. doi:https://doi.org/10.1038/s41398-022-02254-9
  37. Correll C, Rubio J, Inczedy-Farkas G. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry. 2017;74:675-84. doi:https://doi.org/10.1001/jamapsychiatry.2017.0624
  38. Veselinović T, Neuner I. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs. 2022;36:819-58. doi:https://doi.org/10.1007/s40263-022-00935-z
  39. Solmi M, Croatto G, Piva G. Efficacy and acceptability of psychosocial interventions in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. Mol Psychiatry. 2023;28:354-68. doi:https://doi.org/10.1038/s41380-022-01727-z
  40. Bowie C, Bell M, Fiszdon J. Cognitive remediation for schizophrenia: An expert working group white paper on core techniques. Schizophr Res. 2020;215:49-53. doi:https://doi.org/10.1016/j.schres.2019.10.047
  41. Wykes T, Huddy V, Cellard C. A Meta-Analysis of Cognitive Remediation for Schizophrenia: Methodology and Effect Sizes. Am J Psychiatry. 2011;168:472-85. doi:https://doi.org/10.1176/appi.ajp.2010.10060855
  42. Kambeitz-Ilankovic L, Betz L, Dominke C. Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes. Neurosci Biobehav Rev. 2019;107:828-45. doi:https://doi.org/10.1016/j.neubiorev.2019.09.031
  43. Lejeune J, Northrop A, Kurtz M. A Meta-analysis of Cognitive Remediation for Schizophrenia: Efficacy and the Role of Participant and Treatment Factors. Schizophr Bull. 2021;47:997-1006. doi:https://doi.org/10.1093/schbul/sbab022
  44. Vita A, Barlati S, Ceraso A. Effectiveness, Core Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2021;78:848-58. doi:https://doi.org/10.1001/jamapsychiatry.2021.0620
  45. Yeo H, Yoon S, Lee J. A meta-analysis of the effects of social-cognitive training in schizophrenia: The role of treatment characteristics and study quality. Br J Clin Psychol. 2022;61:37-57. doi:https://doi.org/10.1111/bjc.12320
  46. Seccomandi B, Agbedjro D, Bell M. Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophr Res. 2021;228:29-35. doi:https://doi.org/10.1016/j.schres.2020.11.060
  47. Vita A, Barlati S, Ceraso A. Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Psychol Med. 2023;53:3661-71. doi:https://doi.org/10.1017/S0033291722000319
  48. Altman R, Tan E, Rossell S. Factors Impacting Access and Engagement of Cognitive Remediation Therapy for People with Schizophrenia: A Systematic Review. Can J Psychiatry. 2023;68:139-51. doi:https://doi.org/10.1177/07067437221129073
  49. Martini F, Spangaro M, Bechi M. Improving outcome of treatment-resistant schizophrenia: effects of cognitive remediation therapy. Eur Arch Psychiatry Clin Neurosci. Published online 2023. doi:https://doi.org/10.1007/s00406-023-01731-6
  50. Sampedro A, Peña J, Sánchez P. Moderators of functional improvement after integrative cognitive remediation in schizophrenia: toward a personalized treatment approach. Psychiatry Res. 2023;329. doi:https://doi.org/10.1016/j.psychres.2023.115495
  51. Vita A, Barlati S. The Implementation of Evidence-Based Psychiatric Rehabilitation: Challenges and Opportunities for Mental Health Services. Front Psychiatry. 2019;10. doi:https://doi.org/10.3389/fpsyt.2019.00147
  52. Wykes T. Cognitive remediation - where are we now and what should we do next?. Official Journal of the Italian Society of Psychopathology. 2018;24:57-61.
  53. Montemagni C, Del Favero E, Riccardi C. Effects of Cognitive Remediation on Cognition, Metacognition, and Social Cognition in Patients With Schizophrenia. Front Psychiatry. 2021;12. doi:https://doi.org/10.3389/fpsyt.2021.649737
  54. Nibbio G, Barlati S, Cacciani P. Evidence-Based Integrated Intervention in Patients with Schizophrenia: A Pilot Study of Feasibility and Effectiveness in a Real-World Rehabilitation Setting. Int J Environ Res Public Health. 2020;17. doi:https://doi.org/10.3390/ijerph17103352
  55. Vita A, Kakli M, Barlati S. Implementation of cognitive rehabilitation interventions for schizophrenia in low-income countries: An experience from Togo and Benin. Int J Soc Psychiatry. Published online 2023. doi:https://doi.org/10.1177/00207640231181526
  56. Donohoe G, Dillon R, Hargreaves A. Effectiveness of a low support, remotely accessible, cognitive remediation training programme for chronic psychosis: cognitive, functional and cortical outcomes from a single blind randomised controlled trial. Psychol Med. 2018;48:751-64. doi:https://doi.org/10.1017/S0033291717001982
  57. Jagtap S, Romanowska S, Leibovitz T. Can cognitive remediation therapy be delivered remotely? A review examining feasibility and acceptability of remote interventions. Schizophr Res Cogn. 2022;28. doi:https://doi.org/10.1016/j.scog.2022.100238
  58. Medalia A, Saperstein A, Stefancic A. Feasibility and acceptability of remotely accessed cognitive remediation for schizophrenia in public health settings. Psychiatry Res. 2021;301. doi:https://doi.org/10.1016/j.psychres.2021.113956
  59. Mendelson D, Thibaudeau É, Sauvé G. Remote group therapies for cognitive health in schizophrenia-spectrum disorders: Feasible, acceptable, engaging. Schizophr Res Cogn. 2022;28. doi:https://doi.org/10.1016/j.scog.2021.100230
  60. Fernández-Sotos P, Fernández-Caballero A, Rodriguez-Jimenez R. Virtual reality for psychosocial remediation in schizophrenia: a systematic review. Eur J Psychiatry. 2020;34:1-10.
  61. Perra A, Riccardo C, De Lorenzo V. Fully Immersive Virtual Reality-Based Cognitive Remediation for Adults with Psychosocial Disabilities: A Systematic Scoping Review of Methods Intervention Gaps and Meta-Analysis of Published Effectiveness Studies. International nt J Environ Res Public Health. 2023;20. doi:https://doi.org/10.3390/ijerph20021527
  62. Breitborde N, Bell E, Woolverton C. Cost Utility of cognition-enhancing interventions for individuals with first-episode psychosis: a naturalistic evaluation. Cost Eff Resour Alloc. 2021;19. doi:https://doi.org/10.1186/s12962-021-00292-6
  63. Christensen T, Kruse M, Hellström L, Eplov L. Cost-utility and cost-effectiveness of individual placement support and cognitive remediation in people with severe mental illness: Results from a randomized clinical trial. Eur Psychiatry. 2021;64. doi:https://doi.org/10.1192/j.eurpsy.2020.111
  64. Garrido G, Penadés R, Barrios M. Computer-assisted cognitive remediation therapy in schizophrenia: Durability of the effects and cost-utility analysis. Psychiatry Res. 2017;254:198-204. doi:https://doi.org/10.1016/j.psychres.2017.04.065
  65. Patel A, Knapp M, Romeo R. Cognitive remediation therapy in schizophrenia: Cost-effectiveness analysis. Schizophrenia Research. 2010;120:217-24. doi:https://doi.org/10.1016/j.schres.2009.12.003
  66. Wykes T, Stringer D, Boadu J. Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode Participants. Schizophr Bull. Published online 2023. doi:https://doi.org/10.1093/schbul/sbac214
  67. Galderisi S, De Hert M, Del Prato S. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. Eur Psychiatry. 2021;64. doi:https://doi.org/10.1192/j.eurpsy.2020.115
  68. Keepers G, Fochtmann L, Anzia J. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020;177:868-72. doi:https://doi.org/10.1176/appi.ajp.2020.177901
  69. Schmitt A, Maurus I, Rossner M. Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality. Front Psychiatry. 2018;9. doi:https://doi.org/10.3389/fpsyt.2018.00690
  70. Fernández-Abascal B, Suárez-Pinilla P, Cobo-Corrales C. In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis. Neurosci Biobehav Rev. 2021;125:535-68. doi:https://doi.org/10.1016/j.neubiorev.2021.01.005
  71. Firth J, Cotter J, Elliott R. A systematic review and meta-analysis of exercise interventions in schizophrenia patients. Psychol Med. 2015;45:1343-61. doi:https://doi.org/10.1017/S0033291714003110
  72. Sabe M, Kaiser S, Sentissi O. Physical exercise for negative symptoms of schizophrenia: Systematic review of randomized controlled trials and meta-analysis. Gen Hosp Psychiatry. 2020;62:13-20. doi:https://doi.org/10.1016/j.genhosppsych.2019.11.002
  73. Dauwan M, Begemann M, Heringa S. Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2016;42:588-99. doi:https://doi.org/10.1093/schbul/sbv164
  74. Firth J, Stubbs B, Rosenbaum S. Aerobic Exercise Improves Cognitive Functioning in People With Schizophrenia: A Systematic Review and Meta-Analysis. Schizophr Bull. 2017;43:546-56. doi:https://doi.org/10.1093/schbul/sbw115
  75. Shimada T, Ito S, Makabe A. Aerobic exercise and cognitive functioning in schizophrenia: An updated systematic review and meta-analysis. Psychiatry Res. 2022;314. doi:https://doi.org/10.1016/j.psychres.2022.114656
  76. Korman N, Stanton R, Vecchio A. The effect of exercise on global, social, daily living and occupational functioning in people living with schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2023;256:98-111. doi:https://doi.org/10.1016/j.schres.2023.04.012
  77. Dai Y, Ding H, Lu X. CCRT and aerobic exercise: a randomised controlled study of processing speed, cognitive flexibility, and serum BDNF expression in schizophrenia. Schizophrenia (Heidelb). 2022;8. doi:https://doi.org/10.1038/s41537-022-00297-x
  78. Deste G, Corbo D, Nibbio G. Impact of Physical Exercise Alone or in Combination with Cognitive Remediation on Cognitive Functions in People with Schizophrenia: A Qualitative Critical Review. Brain Sci. 2023;13. doi:https://doi.org/10.3390/brainsci13020320
  79. Nuechterlein K, McEwen S, Ventura J. Aerobic exercise enhances cognitive training effects in first-episode schizophrenia: randomized clinical trial demonstrates cognitive and functional gains. Psychol Med. 2023;53:4751-61. doi:https://doi.org/10.1017/S0033291722001696
  80. Husain M, Lisanby S, Kay J. Psychiatry. (Tasman A, Kay J, Lieberman J, eds.). John Wiley & Sons, Ltd; 2015. doi:https://doi.org/10.1002/9781118753378.ch111
  81. Nitsche M, Cohen L, Wassermann E. Transcranial direct current stimulation: State of the art 2008. Brain Stimul. 2008;1:206-23. doi:https://doi.org/10.1016/j.brs.2008.06.004
  82. Lefaucheur J, André-Obadia N, Antal A. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014;125:2150-206. doi:https://doi.org/10.1016/j.clinph.2014.05.021
  83. Begemann M, Brand B, Ćurčić-Blake B. Efficacy of non-invasive brain stimulation on cognitive functioning in brain disorders: a meta-analysis. Psychol Med. 2020;50:2465-86. doi:https://doi.org/10.1017/S0033291720003670
  84. Sloan N, Byrne L, Enticott P, Lum J. Non-Invasive Brain Stimulation Does Not Improve Working Memory in Schizophrenia: A Meta-Analysis of Randomised Controlled Trials. Neuropsychol Rev. 2021;31:115-38. doi:https://doi.org/10.1007/s11065-020-09454-4
  85. Jiang Y, Guo Z, Xing G. Effects of High-Frequency Transcranial Magnetic Stimulation for Cognitive Deficit in Schizophrenia: a meta-analysis. Front Psychiatry. 2019;10. doi:https://doi.org/10.3389/fpsyt.2019.00135
  86. Liu Y, Gu N, Cao X. Effects of transcranial electrical stimulation on working memory in patients with schizophrenia: a systematic review and meta-analysis. Psychiatry Res. 2021;296. doi:https://doi.org/10.1016/j.psychres.2020.113656
  87. Narita Z, Stickley A, DeVylder J. Effect of multi-session prefrontal transcranial direct current stimulation on cognition in schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2020;216:367-73. doi:https://doi.org/10.1016/j.schres.2019.11.011
  88. Sun C, Jiang W, Cai D. Adjunctive multi-session transcranial direct current stimulation for neurocognitive dysfunction in schizophrenia: A meta-analysis. Asian J Psychiatr. 2021;66. doi:https://doi.org/10.1016/j.ajp.2021.102887
  89. Lisoni J, Baldacci G, Nibbio G. Effects of bilateral, bipolar-nonbalanced, frontal transcranial Direct Current Stimulation (tDCS) on negative symptoms and neurocognition in a sample of patients living with schizophrenia: Results of a randomized double-blind sham-controlled trial. J Psychiatr Res. 2022;155:430-42. doi:https://doi.org/10.1016/j.jpsychires.2022.09.011
  90. Poppe A, Ritter F, Bais L. The efficacy of combining cognitive training and noninvasive brain stimulation: A transdiagnostic systematic review and meta-analysis. Psychol Bull. Published online 2023. doi:https://doi.org/10.1037/bul0000406

Downloads

PDF
Authors

Gabriele Nibbio - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

Irene Calzavara Pinton - Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy

Lorenzo Bertoni - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

Antonio Cicale - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

Nicola Necchini - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy;

Daniela Zardini - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

Laura Poddighe - Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy

Jacopo Lisoni - Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy

Giacomo Deste - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy

Stefano Barlati - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy

Antonio Vita - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Department of Mental Health and Addiction Services, ASST Spedali Civili of Brescia, Brescia, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2024 Journal of Psychopathology

How to Cite
[1]
Nibbio, G., Calzavara Pinton, I. , Bertoni, L., Cicale, A., Necchini, N., Zardini, D., Poddighe, L., Lisoni, J., Deste, G., Barlati, S. and Vita, A. 2024. Non-pharmacological interventions to improve cognitive impairment and psychosocial functioning in schizophrenia: a critical review. Journal of Psychopathology. 30, 1 (Feb. 2024). DOI:https://doi.org/10.36148/2284-0249-N455.
  • Abstract viewed - 914 times
  • PDF downloaded - 224 times